WO2004100966A1 - 病態起因物質の生体への接触防止用製剤 - Google Patents
病態起因物質の生体への接触防止用製剤 Download PDFInfo
- Publication number
- WO2004100966A1 WO2004100966A1 PCT/JP2004/006992 JP2004006992W WO2004100966A1 WO 2004100966 A1 WO2004100966 A1 WO 2004100966A1 JP 2004006992 W JP2004006992 W JP 2004006992W WO 2004100966 A1 WO2004100966 A1 WO 2004100966A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- preparation
- living body
- nucleic acid
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention mainly relates to reduction and reduction of body exposure to exogenous rotting factors in daily life, protection against infectious pathogens, and prevention of progression of disease states.
- the basic technology is to reduce the chance of foreign substances binding to living cells, mainly by third substances, and to prevent contact of foreign pathogens with biological surfaces.
- the present invention relates to asthma; rhinitis; sputum measles; food, pollen allergen; or an allergen that is an ignition substance for an allergic reaction such as atopic dermatitis, or a pathogenic microorganism such as various viruses and bacteria.
- the present invention relates to a method for inhibiting or reducing the recognition of a receptor on the side of a living body, preventing or reducing their contact and invasion into the living body, and a therapeutic preparation for mucosal inflammatory disease.
- disorders of biological functions caused by foreign pathogens include allergic reactions and inflammation due to infectious diseases. These allergic reactions and inflammation can elicit unwelcome biological reactions over the medium to long term, not just short-term symptoms. In particular, when the above symptoms persist for a long period of time, the inflammatory response often does not converge and prolongs, irrespective of the disappearance of the pathogenic substance, and this often hinders daily life.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2001-237377).
- the effect of suppressing the allergic reaction described in Patent Document 1 is based on a decrease in the reactivity of the monosite / mace phage by administration of the peptide. That is, the administration of Pectin in Patent Document 1 suppresses the production of IL-15 (interleukin-15), the production of IL-4 (interleukin-14), and the enhancement of IFN-gamma production by monosite / macrophage. It acts on.
- Pectin is also used for the purpose of achieving stable dispersion distribution and wetting of substances in a solution, and is added as a stabilizer to various drink products and formulations (for example, Patent Document 2: Japanese Patent Application Laid-Open No. 2001-2001) — See Japanese Patent Publication No. 6 489 5).
- Patent Document 2 describes the effect of the addition of Pectin to eye drops on the sustained effect of the preparation, which also prolongs the local retention of the preparation by wet distribution.
- Patent Document 3 Japanese Patent Application Laid-Open No. 2000-5500888.
- the preparation of Patent Document 3 inhibits an enzyme present on the surface of a virus that functions to cleave sialic acid, thereby preventing virus particles from being released from the surface of a living cell.
- sialyl lactose-containing polymers show strong inhibitory activity against H1 virus HA
- polymers in which sialic acid monosaccharide is bonded as C- or S-glycoside have strong inhibitory activity against H3 virus HA. It is reported to have.
- a drug containing a low molecular weight sialic acid derivative which exhibits an inhibitory effect on two types of membrane proteins (sialidase and hemagglutinin) as an active ingredient has been disclosed (for example, Patent Document 4). : Japanese Patent Application Laid-Open No. 2001-134).
- vaccination-based prophylaxis requires some time from vaccination until antibody formation. Depending on the target pathogen, vaccination must be divided into multiple doses. As a result, inflammation of the allergic reaction ⁇ influenza may occur before the effect of the vaccine appears, and in some cases vaccination has been ineffective.
- the present inventors have focused on establishing a new molecular interaction between these pathogens and living organisms against allergen groups or pathogens such as viruses, and have established contact between pathogenic substances and living organisms.
- the goal was to prevent or reduce DISCLOSURE OF THE INVENTION-
- the present inventors have studied the allergen groups such as cryj 1 and cryj 2 which are cedar pollen allergens, or the physical properties, three-dimensional structure, and physiochemical functions of pathogens such as pathogens such as influenza. We focused on preventing them from coming into contact with living organisms.
- a polysaccharide on the cell surface functions as a contact point with the outside world of a living body, and is linked as a sugar chain component of a glycoprotein on the cell surface.
- mucopolysaccharides / peronic acids in mucin and the like are constituents.
- the structural similarity is preserved between the polysaccharides linked to the cell surface and the freely distributed peronic acid-containing and mucopolysaccharides.
- influenza virus forms a membrane envelope containing hemagglutin and neuraminidase (sialidase), two surface spike proteins that interact with sialyl oligosaccharides on host (erythroid) cells.
- hemagglutinin is known to adhere to host cell structures containing sialic acid, galactose and N-acetyldarcosamine.
- the present invention focuses on such an enzyme-to-substrate binding mode and utilizes the specific or non-specific competitive binding relationship between a substrate and its analogous molecules for saccharides and proteolytic enzymes, thereby allowing pathogens such as influenza viruses and biological And contact with it.
- the present inventors have designed and constructed a substance exhibiting physical properties to prevent the above-mentioned pathological substance from coming into contact with the surface of a living body, thereby preventing the onset of the above-mentioned pathogenic substance or reducing the pathological state. Realize.
- viral particles having a structure in which an envelope covers a nucleic acid and various positively charged allergens exhibit a variety of three-dimensional structures, and a partial region of a negatively charged polysaccharide tends to be closely distributed. Should be.
- negatively charged nucleic acid and amino acid molecules also have the property of attracting positively charged allergens and virus particles in microscopic spaces.
- various molecular complexes also contain conditions that are unlikely to be connected and aggregated, that is, substances having a dispersing activity.
- the present invention also includes a therapeutic preparation for mucosal inflammatory disease containing a peronic acid-containing polysaccharide or nucleic acid as a therapeutic preparation for an endogenous factor.
- pectin functions as a substrate for an enzyme that is an allergen causing pollinosis, and prevents pollen from contacting a living body.
- a nucleic acid molecule having a strong negative charge surrounds the surface of a positively charged pollen or virus, thereby preventing contact with a living body.
- various endogenous inflammation-related components are incorporated into a three-dimensional structure or masked from mucous membranes and inflammatory cells to exert an action of eliminating or mitigating inflammation around the mucosa.
- FIG. 1 is a graph showing the relationship between the concentration of cedar pollen extracted antigen and the histamine release rate.
- FIG. 2 is a graph showing the synergistic relationship between pectin and DNA with respect to the inhibitory effect on the histamine release rate.
- FIG. 3 is a view showing a use test result of the eye drop preparation of the present invention.
- the preparation for preventing contact of the pathogen-causing substance with the living body includes pectin-containing or ⁇ ronic acid-containing polysaccharide, which is a pectin-related ⁇ ronic acid-containing polysaccharide, and a derivative of ⁇ ronic acid-containing polysaccharide. At least any one of the following pectin-derived substances:
- Pectin is one of the polysaccharides that constitute the plant cell wall, and contains a large amount of polygalacturonic acid bound to galataturonic acid, and in addition to rhamnogalacturonic acid, which is alternately bound to rhamnose and galatatuic acid. Is contained in a small amount in the main chain, and one or more of arabinose, xylose, fucose, rhamnose and galactose are bonded in comb form to the rhamnose residue of rhamnogalataturonan as a side chain.
- pectin-related polyuronic acid-containing polysaccharides include arginic acid, which is abundant in seaweeds, and dermatan sulfate, chondroitin sulfate, chondroitin, hyaluronic acid, which are abundant in skin, cartilage and organs in the animal kingdom. Heparin and the like.
- pectin uses galacturonic acid
- alginic acid uses mannuronic acid and guluronic acid
- hyaluronic acid uses glucuronic acid
- de / rematan sulfate uses iduronic acid
- chondroitin sulfate uses glucuronic acid.
- Heparin has glucuronic acid and iduronic acid as the main constituents, respectively.
- pectin-derived substance refers to a substance obtained by subjecting pectin to heat, pressure, oxidation, or the like, or chemically modifying pectin to improve the physical properties of pectin.
- pectin is contained in fruits such as apples in a little less than about 10% of its dry weight
- alginic acid is contained in brown algae such as Comp in about 20% of its dry weight
- Hyaluronic acid which is a pectin-related ⁇ ronic acid-containing saccharide, is Dermatan sulfate for skin, tendons, internal organs, etc., chondroitin sulfate for sharks and other cartilage (20 to 40% of dry weight), skin, etc., heparin for organs, etc. Respectively.
- Peruronic acids such as glucuronic acid, galataturonic acid, mannuronic acid, isuronic acid, and guluronic acid are part of the chemical structure of monosaccharides such as gnorecose, galactose, mannose, idose, and growth (alcohol at position 6). ) Is oxidized to have a sulfonic acid group.
- Mucopolysaccharides which are related to peronic acid-containing polysaccharides, are present in connective tissues and body fluids of animals among heteropolysaccharides and contain amino acids. Mucopolysaccharides are bound to proteins in vivo, and a complex of mucopolysaccharides and proteins consisting of a repeating disaccharide structure is called proteoglycan.
- proteoglycans One of these proteoglycans is mucin.
- Mucin is a major glycoprotein of mucus that covers the lumen of the digestive tract, such as the trachea and gastrointestinal tract, and the reproductive tract. Mucin is also found in large amounts in plants such as okra, moroheiya, tsumurasaki, ashitaba, sweet potato and nameko.
- the pathogenic substances include allergens including cedar pollen and the like, and pathogenic microorganisms including influenza virus and the like.
- the major allergen of cedar pollen is a saccharide-degrading enzyme that functions during pollen fertilization.
- This saccharide-decomposing enzyme has a Cryjl having a molecular weight of about 450,000 daltons and an isoelectric point of 8.9 to 9.2, and a molecular weight of about 3,700,000 daltons and an isoelectric point of 9.5. These are two of Cryj 2. Therefore, the sera of many cedar hay fever patients recognize Cryjl and Cryj2 as allergens.
- Vectin contained in the anti-contact preparation according to the present embodiment is an enzyme digested and decomposed by the above-mentioned Cryj 1 which is a pectate lyase functioning at the time of pollen fertilization and the above-mentioned Cryj 2 which is a polymethylgalacturonase. It is a substrate and a water-soluble polysaccharide. Furthermore, Cryj1 and Cryj2 are also highly homologous to saccharide-degrading enzymes of other plants.
- the above-mentioned pectin and pectin related ⁇ - ⁇ uronic acid-containing polysaccharide or pectin-derived substance cause an enzyme-substrate reaction with Cryj1 or Cryj2 on the pollen surface. Furthermore, since the above-mentioned substrates such as pectin are macromolecules, new substrate structures are presented one after another, no matter how much the enzyme is digested.
- Allergens only trigger an allergic reaction when recognized by antibodies. From this fact, if any third molecule modifies the three-dimensional structure of the allergen to inhibit the binding of the antibody molecule to the allergen itself, no allergic reaction is induced.
- the pectins contained in the contact-preventing preparation according to the present embodiment intervene between pollen and immunoglobulin E of a hay fever patient to inhibit the binding of both, thereby causing an allergic reaction to occur. Can be prevented. As described above, interposing pectin or a related substance between pollen and living cells is effective in preventing a pollen allergic reaction.
- hemagglutinin is an essential protein for the virus to bind to the gandarioside-sialic acid-containing glycoprotein receptor on the host cell membrane, and neuraminidase (sialidase) cleaves sialic acid from the receptor on the cell membrane It has a function to do.
- influenza exerts its infectivity by recognizing sialic residues of glycoproteins by hemagglutinin and neuraminidase, which are the starting points for living cells.
- host-side proteases, clotting factor factor 10, and bacterial proteases play a critical role in the cleavage of hemagglutin.
- the factor 10 that functions here is inhibited by heparin, a peronic acid. From these facts, repetitive galataturonic acid sequence by pectin and repetitive sequence of dalcuronic acid and iduronic acid by heparin intervene between virus and living cells to inhibit the binding of both.
- peronic acids such as pectin and heparin are useful for preventing unwelcome biological reactions due to the inhibition of the pathogen-causing substances from entering the living body.
- examples of the buffering agent include boric acid or a salt thereof (borax or the like), citric acid or a salt thereof (sodium taenoate or the like), phosphoric acid or a salt thereof (sodium monohydrogen phosphate or the like) And tartaric acid or a salt thereof (such as sodium tartrate), dalconic acid or a salt thereof (such as sodium dalconate), acetic acid or a salt thereof (such as sodium acetate), various amino acids and the like, and combinations thereof.
- solubilizer examples include polyethylene glycol, propylene glycol and the like.
- tonicity agent examples include sodium chloride, potassium chloride, mannitol, propylene glycol and the like.
- the stabilizer examples include sodium edetate, cyclodextrin, sulphite, citric acid or a salt thereof.
- thickener examples include polyethylene glycol, polyvinyl alcohol, polyvinylinolepyrrolidone, hydroxyxetinoresenorelose, hydroxypropinolemethylcellulose, methylcenorelose, and sodium chondroitin sulfate.
- Examples of the chelating agent include sodium edetate, sodium citrate and the like.
- Examples of the ⁇ ⁇ regulator include hydrochloric acid, citric acid or a salt thereof, boric acid or a salt thereof, phosphoric acid or a salt thereof, acetic acid or a salt thereof, tartaric acid or a salt thereof, sodium hydroxide, potassium hydroxide, sodium carbonate, And sodium hydrogencarbonate.
- cooling agent examples include menthol, borneol, camphor, geranyol, limonene, eugenol, heart oil, eucalyptus oil and the like.
- Pharmaceutical components include, for example, steroids, decongestants (naphazolin hydrochloride, tetrahydrozolin hydrochloride, fenirrefrine hydrochloride, etc.), anti-inflammatory agents (astringents such as neostigmine methyl sulfate, ipsiron monoaminocaproic acid, allantoin, berberine chloride) , Zinc sulfate, lysozyme chloride), antihistamines (diphenhydramine hydrochloride, isotipendyl hydrochloride, chlorpheniramine maleate, etc.), vitamins [vitamins A and its esters (for example, acetate and palmitate), activated vitamin B2, vitamin B6, vitamin B12, vitamin E and its esters (for example, carboxylic acid ester), etc., and amino acids (L-aspartic acid) Potassium, magnesium L-aspartate, aminoethylsulfonic acid, chondroitin sul
- the pH of the composition for external use of the present invention is not particularly limited as long as it is within a biologically acceptable range, and is usually in the range of pH 4 to 10 and preferably 5 to 8.5.
- the dose of the composition for external use of the present invention is not particularly limited as long as it is within a biologically acceptable range. For example, when used as eye drops, nasal drops, or sprays, a single dose is 50 to 200. L is preferably administered 4 to 6 times a day.
- a plant-derived component in addition to the above-mentioned main component of the pectin.
- the origin of pectins themselves is also required for various plants, and the isolated products at various stages of the treatment process, such as hydrolysis of plant components, are pectins as active ingredients and become formulations containing other plant-derived components.
- plant-derived components are classified into water-soluble and water-insoluble fibrous materials, proteins, lipids, and sugars, and plant fibers, alkaloids, saponins, tannins, catechins, aponysins, bitter substances, mucous substances, and glycosides. , Flavonoids, vitamins, organic acids, minerals, etc.
- plant-derived components are as diverse as aromatics, natural bactericidal actions, carbohydrate surfactants, anti-inflammatory actions, hyaluronidase inhibitory actions, and protein saccharification reaction inhibitory actions. For this reason, the use of plant-derived components has expanded to a wide range of fields such as pharmaceuticals, cosmetics, and foods.
- the preparation containing the above-mentioned various plant components as active ingredients together with pectin, pectin-related ⁇ ronic acid-containing polysaccharide or pectin-derived substance exhibits a complex function together with the pectin, It is useful for preventing unwelcome biological reactions including allergic reactions.
- the formulation of the present invention also includes a common formulation additive containing an electrolyte, various medicinal components, and the like.
- the above-mentioned plant-derived components are required to be derived from a cedar species plant among various plants.
- the separated products at various stages of the processing process such as crushing and hydrolysis of the cedar component consisting of young leaves, branches, roots, stems, seedlings, calli, etc., contain active ingredients including pectins It becomes a formulation.
- materials exhibiting flexible and active functions such as calli, growth points, young trees, etc. are preferred as starting materials.
- the blending ratio of various cedar-derived components to pectin, pectin-related ⁇ ronic acid-containing polysaccharides or pectin-derived substances can be arbitrarily set. Furthermore, in the process of processing and sorting the cedar components, components extracted as a pectin-containing fraction may be used. Also, in the preparation of the present embodiment, it is preferable to add various components usually used for preparing an external preparation in addition to the essential components.
- the contact-preventing preparation according to the present embodiment may contain at least one of other saccharides, polymer compounds, and nonionic surfactants.
- Examples of the high molecular compound include polyvinyl alcohol, polyvinylpyrrolidone, hydroxyxetinoresenorelose, hydroxypropinolemethylsenorelose, methylcellulose, cyclodextrin, and the like.
- Examples of the agent include polyoxyethylene higher fatty acid ester, polyoxyethylene sorbitan higher fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, and sucrose fatty acid ester. More specifically, for example, polyoxyethylene curing Castor oil, polyoxyethylene sorbitan monooleate and the like.
- a chelating agent is effective for preventing water insolubilization by Ca and Mg, and a lipase or the like is effective for decomposing fat components.
- the degree of freedom of the application method and dosage form of the preparation for preventing contact can be increased.
- Each of the contact-preventing preparations according to the present embodiment can be effectively prevented from contacting a living body with a pathogenic substance by being placed around the living body.
- the disposition of the above-mentioned preparation for contact prevention around a living body includes administration of the above-mentioned preparation for contact prevention to the surface of a living body.
- the above-mentioned contact-preventing preparation is fixed to an attachment means such as a mask, goggles, a hat, clothing, a filter such as an air conditioner, a tape, or the like by an appropriate method. It is useful to wear it.
- an attachment means such as a mask, goggles, a hat, clothing, a filter such as an air conditioner, a tape, or the like.
- it is effective to distribute the above preparation around the local surface of the body where allergens and pathogens easily adhere.
- it is effective to directly administer the above-mentioned contact-preventing preparation to the mucous membrane or skin that is wet and not covered with clothes, and on which the IgE antibody or sugar chain appears on the body surface. Therefore, external dosage forms such as eye drops, nasal drops, ear drops, inhalations, gargles, sprays, coatings, patches, washings, enema, etc. It is.
- the preparation for preventing contact of a disease state-causing substance with a living body contains at least one of a nucleic acid and a derivative of the nucleic acid.
- the derivative of the nucleic acid refers to a substance obtained by subjecting DNA or RNA to a decomposition treatment, or a substance obtained by performing chemical modification to improve the properties of the nucleic acid.
- the nucleic acids are negatively charged macromolecules.
- DNA is a stable structure
- RNA is a fragile structure that performs short-term functions. These form a complex with saccharide ⁇ protein and It is known to be active, and is further cut or synthesized by enzymes into larger sequences.
- nucleic acids have the property of attracting positively charged molecules such as liposomes. This is due to the fact that in nucleic acids, the biological molecule has at least one negative charge per pentose, so that DNA and RNA contain one negative charge per nucleotide. That is, unlike ordinary small molecules, nucleic acids have large negative charges throughout the macromolecules.
- the nucleic acids are strongly attracted to a pathogenic substance such as a positively charged allergen or a pathogenic microorganism, and adhere to the surface of the pathogenic substance. This causes the pathogens to lose charge and not only lose their ability to adhere to negatively charged cell surfaces, but also lose contact with specific receptors on the body surface.
- a nucleic acid is a huge molecule is an overwhelmingly advantageous physical property compared to other small molecules in that it covers the surface of a disease-causing substance.
- the preparation containing the nucleic acid or the derivative of the nucleic acid according to the present embodiment exerts a function of preventing the binding ability of the pathogen before reaching the surface of the living body.
- nucleic acids are water-soluble heteropolysaccharides that form complexes with saccharides, and are chain-like macromolecular compounds in which nucleotide units are long connected by phosphodiester bonds.
- one of the saccharide-degrading enzymes, Cryjl and Cryj2 is also known as an allergen in most cedar pollinosis. Since allergens cause an allergic reaction only after being recognized by the antibody, allergy occurs when IgE antibodies cannot recognize the allergen itself due to the binding of the heteropolysaccharide nucleic acids and their derivatives to the allergen. No response is elicited.
- the nucleic acids of the preparation for preventing contact of the present embodiment intervene between cedar pollen and immunoglobulin E of hay fever patients to inhibit the binding of both, thereby preventing the initiation of allergic reaction. Therefore, when distributing a nucleic acid or a derivative of a nucleic acid to an appropriate region on the surface of a living body, the surface can be attracted to various allergens such as positively charged pollen, thereby isolating the negatively charged living body surface from pathogenic substances. It becomes an effective means for preventing and reducing the onset of pathological conditions.
- wearable means such as a mask or goggles, which form a complex of nucleic acids having a structure with high affinity for allergens and administer them to the mucous membrane of the living body, or cover the above nucleic acids with openings such as mouth, eyes, and nose.
- a mask or goggles which form a complex of nucleic acids having a structure with high affinity for allergens and administer them to the mucous membrane of the living body, or cover the above nucleic acids with openings such as mouth, eyes, and nose.
- the above-mentioned contact-preventing preparation can exert the above-mentioned function effectively when used in combination with various electrolytes. This is because the electrolytes can promote the deposition and accumulation of nucleic acids and positively charged pathogens due to the chaotropic effect.
- micelle formation of a hydrophobic molecule by a surfactant is also effective because of the affinity between nucleic acids and a disease-causing substance.
- RNA is fragmented in some places and has various arrangements with respect to foreign substances. By doing so, the function of surrounding foreign substances can be strengthened.
- nucleic acid sequences having high affinity for the disease-causing substance by screening.
- nucleic acid components it is also possible to add various drug components usually used for preparing an external preparation.
- the nucleic acid or the derivative of the nucleic acid When the nucleic acid or the derivative of the nucleic acid is developed in a solvent in the above contact-preventing preparation, these substances are unevenly distributed due to the disease-causing substance and the surrounding environment, and the penetrating power, emulsifying power, detergency, and scouring power of the preparation Power may be insufficient. In such a case, it is effective to add at least one of other saccharides, nonionic surfactants, and polymer compounds.
- Examples of the high molecular compound include polyvinyl alcohol, polyvinylpyrrolidone, hydroxyxetinoresenorelose, hydroxypropinolemethinoresenorelose, methylcellulose, cyclodextrin, and the like.
- Examples of the activator include polyoxyethylene higher fatty acid ester, polyoxyethylene sorbitan higher fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester and Examples thereof include sucrose fatty acid esters, and more specifically, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monooleate, and the like.
- a chelating agent is effective for preventing water insolubilization by Ca and Mg, and a lipase or the like is effective for decomposing fat components.
- nucleic acids can be improved safely when a molecular structure that easily spreads among nucleic acids is formed by the coexistence of other saccharides such as trehalose, which enhances the spreadability in an aqueous solution.
- the penetrating power, emulsifying power, detergency, and scouring power of the above-mentioned preparations are sufficiently improved. Thereby, the degree of freedom of the application method and dosage form of the above-mentioned contact-preventing preparation is also increased.
- Each of the above-described preparations for preventing contact according to the present embodiment can be effectively prevented from contacting a living body with a pathogenic substance by being placed around a living body.
- the disposition of the above-mentioned preparation for contact prevention around a living body includes administration of the above-mentioned preparation for contact prevention to the surface of a living body.
- the above-mentioned contact-preventing preparation is fixed to a mounting means such as a mask, a god, a hat, clothing, a filter such as an air conditioner, a tape, or the like by an appropriate method. It is useful to wear it.
- the preparation for preventing contact of a pathogenic substance with a living body contains pectin. Or at least one of vectin analogs that are peronic acid-containing polysaccharides and vectin derivatives that are derivatives of peronic acid-containing polysaccharides. Contains at least one of them.
- pectin, pectin-related poronic acid-containing polysaccharide or pectin-derived substance, and the nucleic acid or the derivative of the nucleic acid according to the present embodiment are all naturally-derived water-soluble polymers having a negative charge.
- the above-mentioned polysaccharides and nucleic acids have in common that they are difficult to be separated even after being subjected to extraction with phenol and chloroform and the operation of precipitation with ethanol and acetic acid.
- pectins and nucleic acids are structures that show a clear difference in their molecular constituent elements and three-dimensional forms, respectively.
- nucleic acids are hydrophilic molecules. Therefore, the nucleic acids are deposited and accumulated on the counterpart substance by the chaotropic effect, and have a property of being separated from ordinary saccharides and proteins.
- Pectins are substances in which one or more of arabinose, xylose, fucose, rhamnose and galactose are linked in a comb-like manner to the rhamnose residue of rhamnogalataturonan as a main chain. That is, as a result of water molecules being incorporated as a group into pectins by hydrophobic hydration during hydration based on structural characteristics, the concentration of nucleic acids in free space is increased, and at the same time, sodium salts, potassium salts, and magnesium salts Positively charged ions such as are attracted to the peronic acid end.
- the chaotropic effect is enhanced and the attractive binding distribution to the nucleic acids on the pollen surface is promoted.
- this phenomenon further enhances the allergen surrounding by pectonic and other peronic acid-containing polysaccharides by producing a positive feedback effect that highlights Cryj1 and Cryj2 from the lipid structure on the pollen surface. Become.
- peronic acid examples include glucuronic acid, galataturonic acid, mannuronic acid, iduronic acid, and gnoleronic acid, and the chemical chemistry of monosaccharides such as glucose, galactose, mannose, idose, and growth, respectively.
- a part of the structure is oxidized to form a structure with a carboxylic acid group.
- a polysaccharide containing longonic acid in addition to pectin, which is abundant in vegetables and fruits, abundant in seaweeds Alginate, and dermatan sulfate, chondroitin sulfate, chondroitin, hyaluronic acid, heparin, etc., which are abundant in skin, cartilage and organs in the animal kingdom, are known to play a role in protecting tissues, moisturizing and ensuring flexibility.
- these peronic acid-containing polysaccharides have interchangeability recognized by a common enzyme due to structural similarity.
- these peronic acid-containing polysaccharides are also foods that are consumed on a daily basis, and do not adversely affect human functions.
- nucleic acids are also incorporated into all living organisms as blueprints, and there is no danger in applying them to living organisms for external use or taking.
- the pathogen When an exogenous pathogen is present on the surface of a living body in the reaction space, the pathogen causes contact with a receptor molecule on the surface of the living body to generate a pathogenic stimulus.
- a pathogenic substance such as an allergen
- a pathogenic substance such as an allergen
- the modifier around the receptor molecule and the heterogeneity of the pathogen-causing substance surface even with the above-mentioned peronic acid-containing polysaccharides or nucleic acids, some pathogen-causing substances do not come into contact with the biological surface. Inevitable.
- one of the causes is that the nucleic acid exerts the property of easily capturing the third substance having a positive charge, and the It also functions to capture foreign substances around the originating substance.
- the disease-causing substance from which the mask due to the contaminant has been removed is more clearly recognized and surrounded by the peronic acid-containing polysaccharide. Therefore, most of the pathogens in the reaction space are blocked from the biological surface receptor, and the subsequent contact reaction can be completely prevented. Conversely, hydrophobic contaminants and the like are easily recognized by the peronic acid-containing polysaccharide.
- the envelope and spike proteins are tightly covered by the same mechanism.
- molecules that work on living cells on the surface of the virus are placed in an environment where they cannot make contact with living organisms.
- one negatively-charged nucleic acid per nucleotide and one regular or random polysaccharide sequence when opposed to a group of molecules that are present on the surface of a living body and have different three-dimensional structures and charge characteristics.
- Pectins that have an ester or oxidized terminal at the top have a high isoelectric point It exerts an excellent function to select a group having different characteristics from a group of molecules.
- pectin, pectin-related polyuronic acid-containing polysaccharide or vector-derived substance, and nucleic acid or a nucleic acid-derived substance as main functional components means that the affinity for peronic acid-containing polysaccharide is high. This will constitute a biologically superior and practical formulation for performing molecular selection based on the nature or affinity for nucleic acids or preventing contact of pathogenic substances with living organisms.
- the above-mentioned preparation for preventing contact is also effective against inflammatory skin diseases including atopic dermatitis.
- inflammatory skin diseases including atopic dermatitis various inflammatory cells are released from inflammatory cells, which stimulate or damage the skin surface cells and the like. For this reason, the pathogenesis is caused by the activation of a vicious circle that accelerates the inflammation and exacerbation of symptoms such as itching due to migration of re-inflammatory cells.
- the preparation containing the pectin or vectin-related polyuronic acid-containing polysaccharide and the nucleic acid according to the present embodiment is applied to an inflamed topic or sprayed, the pectin or the nucleic acid is released to the skin surface. It protects the skin surface by adsorbing and covering inflammatory secretions that are distributed and by covering various irritants coming into contact with the site of skin inflammation from the outside world.
- the contact preventive preparation stabilizes the cell membrane and thus the cell function by adsorbing the inflammatory component from outside the cell.
- nucleic acids have a general affinity for signal molecules transmitted into the nucleus is also useful for preventing vicious circles.
- pectins and nucleic acids are due to their synergistic function of capturing inflammatory secretions and exogenous stimulants from the chaotropic effect of hydration and enhancement of ionic strength.
- peronic acids alone give a sticky feeling, and the effect of nucleic acids alone is diminished.
- the preparation for preventing contact containing pectin, pectin-related polybutyric acid-containing polysaccharide or a derivative thereof and a nucleic acid or a derivative of a nucleic acid according to the present embodiment is prepared by placing the preparation around the living body with an external preparation.
- the method has a remarkable effect.
- the installation of the contact-preventing preparation around the living body includes administration of the contact-preventing preparation to the surface of a living body.
- the contact-preventing preparations containing pectin or pectin-related ⁇ uronic acid-containing polysaccharide or a derivative thereof, and containing a nucleic acid or a derivative of a nucleic acid include eye drops, nasal drops, It is used as an external preparation for any of ear drops, inhalation, gargle, spray, coating, patch, lavage, and enema.
- the above-mentioned preparation for contact prevention can be applied to any wearable device such as a mask, goggles, hat, clothing, a filter such as an air conditioner, or a tape, and is effective in preventing the onset of a disease state.
- various external preparations containing both the above-mentioned pectins and nucleic acids as constituents also exhibit a function of elevating mutual affinity in addition to unique binding affinity.
- nucleic acids or nucleic acid-derived substances exert the effect of adsorbing and removing various contaminants present on the surface of the disease-causing substance, the peronic acid-containing polysaccharide can easily remove allergens or other pathogen-derived enzyme proteins. A recognizable spatial environment is established.
- the polysaccharide containing humic acid exerts an action of adsorbing and excluding various contaminants present on the surface of various carcinogens and the like
- the above carcinogens and the like can be easily produced by nucleic acids or nucleic acid derivatives. They will recognize pathogens. That is, the mixture of pectin and nucleic acid is useful for improving the discrimination of various pathogens and constructing a preparation that avoids the onset of the pathological condition.
- these substances may be unevenly distributed, resulting in insufficient penetration, emulsification, detergency, and scouring power of the above products.
- it is effective to add at least one of other saccharides, nonionic surfactants, and high molecular compounds.
- Examples of the high molecular compound include polyvinyl alcohol, polyvinylpyrrolidone, hydroxyxetinores / relose, hydroxypropinolemethinoresolesolose, methylcellulose, and cyclodextrin.
- Examples of the activator include polyoxyethylene higher fatty acid ester and polyoxyethylene sorbitan. Examples include higher fatty acid esters, glycerin fatty acid esters, sorbitan fatty acid esters, and sucrose fatty acid esters, and more specifically, for example, polyoxyethylene hydrogenated castor oil, polyoxyethylene sonolebitan monooleate, and the like.
- a chelating agent is effective for preventing water insolubilization by Ca and Mg, and a lipase or the like is effective for decomposing fat components.
- the penetrating power, emulsifying power, detergency, and scouring power of the above-mentioned preparation are sufficiently improved. Thereby, the degree of freedom of the application method and dosage form of the preparation for preventing contact can be increased.
- the preparation for preventing contact of a disease state-causing substance with a living body includes an antiallergic drug such as an antihistamine in the contact prevention preparation according to each of the above embodiments.
- the preparation for preventing contact according to the present embodiment complements the function of the preparation for preventing contact according to each of the above embodiments for preventing the pathogenic substance from contacting the surface of a living body, prevents the onset of allergic symptoms, or reduces allergic symptoms. It is alleviating.
- the anti-allergic drug such as the above-mentioned antihistamine, a therapeutic agent conventionally used can be used.
- the living body may have been already exposed to a large amount of the pathogen. It is also conceivable that a new disease-causing substance arrives at the stage when the used contact-prevention preparation is disappearing from the topical area of application. In these cases, the preparation for preventing contact according to each of the above embodiments may have insufficient capture of the pathogenic substance.
- the added anti-allergic drug does not cause allergic symptoms due to pathogens that could not be captured.
- the onset can be suppressed or reduced. Therefore, the components such as the above-mentioned antiallergic drugs exhibit a function of complementing the function of suppressing the onset of the disease state, which suppresses the development of the disease state. Furthermore, in cases where edema or exudate appears on the surface of the living body and hinders the development of the above-mentioned preparation for preventing contact, it is possible to contain a pharmaceutically active ingredient for removing edema and the like.
- the contact-preventing preparation according to the present embodiment is applied to an external preparation for eye drops, nasal drops, ear drops, inhalation, gargle, spray, enema, and bathing.
- Anti-allergic drugs such as antihistamines prevent or reduce the onset of allergic symptoms in the method of preventing contact of pathogenic substances with living bodies by ear drops, inhalation, spray application, gargling, bathing, and enema. Can be.
- the pollen formation means a state in which a plurality of pollen particles are linearly connected
- the aggregation of pollen means a state in which a plurality of pollen particles form a barta. In both cases, the pollen particles are trapped by the medium and free movement is suppressed, and the larger the degree, the greater the pollen enclosing ability.
- Japanese cedar pollen is distilled water, aqueous solution containing Pectin (Wako Pure Chemical Co., Ltd., # 168-8-0555), aqueous solution containing glycerin, aqueous solution containing pectin and glycerin, DNA (Daiwa Kasei; DN-JA0904) , DK-JB0218), RNA (Sigma; R6625), amino acid and glycerin-containing aqueous solution, and incubate at room temperature for 10 minutes.
- the base was added to prepare a pollen developing solution.
- Each of the pollen spreads was allowed to drip on a slide glass, dried, stained with a ruthenium red and a gentian violet alcohol solution, and the pollen formation was examined by microscopic examination.
- canolepox methinoresenorelose, methinoresenorelose, torenodulose, and cluster dextrin enhanced the action of pectin.
- sugar ester and polydali ester exhibited an effect of dispersing pollen that was agglomerated or connected.
- Various amino acids have the property of easily polluting pollen, but glutamic acid and aspartic acid have enhanced the pollen-surrounding effect of vectin.
- boric acid promoted pollen aggregation, but also showed pollen rupture.
- pectin prevents binding of leukocytes from pollen allergic carriers to pollen, thereby inhibiting granule release from leukocytes and accumulation of various types of leukocytes.
- the results of this in vitro experiment indicate that pectin prevents the onset of allergic reaction caused by cedar pollen in the biological reaction field, using the inhibition of pollen recognition by leukocytes including basophils as an action point.
- nucleic acids have a large amount of negative charge throughout the macromolecule, since one nucleotide has one negative charge. Therefore, it is judged that the nucleic acids exerted a function of preventing the allergen from adhering to the surface of the negatively charged leukocyte by covering the entire positively charged pollen with pectin in a band-like manner.
- a control sample using only the buffer, a sample containing pectin in the buffer, and a sample containing nucleic acid were prepared, and the histamine release rate with respect to the addition of allergen was compared.
- a cedar pollen extracted antigen was used as an allergen.
- FIG. 1 is a graph showing the relationship between the concentration of cedar pollen extracted antigen (allergen) and the histamine release rate.
- the open circles in the graph show the results in the sample containing 0.03% pectin, and the filled circles show the results in the control sample using only the buffer solution.
- FIG. 2 is a graph showing the synergistic relationship between pectin and DNA with respect to the inhibitory effect on the histamine release rate. As shown in FIG. 2, a satisfactory histamine release-preventing ability cannot be obtained only with the sample containing 0.03% pectin. However, a significant histamine release inhibitory effect was obtained by adding DNA to a concentration of 0.3%.
- RNA in place of DNA could significantly suppress histamine release by pollen extract.
- the neuraminidase activity of type A influenza virus was analyzed by an enzymatic reaction with a synthetic chromogenic substrate (Nichirei; Genestat Flu Kit). This enzymatic reaction is based on the ability of neuraminidase to cleave acetyl neuraminic acid, indicating that the deeper the blue color of the test solution, the higher the enzymatic activity.
- a virus sample collected from the pharynx of a person infected with type A influenza was divided into a control sample and a sample for evaluating the effect of pectins on the enzymatic activity.
- the control sample in which 30 ⁇ l of distilled water was added to the reaction solution exhibited a vivid blue color due to the drop of the test solution.
- the evaluation material containing 0.05% pectin (Genu; USD-H) in a neuraminidase activity-positive sample no color was observed in the same volume reaction solution, and the sample was negative.
- the peronic acid-containing polysaccharides of pectin and heparin attenuate the enzymatic activity of neuraminidase in influenza virus
- the nucleic acid is a peronate-containing substrate such as pectin or heparin by neuraminidase in the reaction environment. It has been shown to have the effect of promoting the classification of species. Therefore, when nucleic acid is involved, the ability to recognize pectins by neuraminidase is improved.
- the preparation for preventing contact according to the present invention was applied to an ophthalmic preparation and a nasal preparation, and a use test was conducted by a subject.
- the ophthalmic formulation and the nasal formulation according to the present example contain pectin (Genu; typDF, etc.) and DNA (Daiwa Kasei) at the following contents.
- Pectin and DNA are as follows: Pectin 0.03 to 1.0%, DNAO.05 to 1.0%, 0.5% Pectin + 0.5% DNA, 0.8% Pectin + 0.2% DNA, 0.2% Pectin + 0.8% DNA.
- the subjects who were pollen allergic subjects were examined for the degree of improvement of itch, the duration and the feeling of use (the degree of discomfort) when each ophthalmic preparation was administered when an allergic reaction occurred.
- the obtained results were evaluated according to the following evaluation criteria.
- AAA Itching was greatly reduced AA: Itching was reduced A: Itching was slightly reduced B B: Itching did not change B: Itching became severe Evaluation criteria for the degree of sustained improvement of itching
- AAA AA lasted more than 180 minutes: AA lasted more than 12 ⁇ minutes A: More than 60 minutes lasted BB: More than 30 minutes and less than 60 minutes B: Less than 30 minutes Evaluation criteria for usability (degree of discomfort)
- AAA No discomfort at all AA: Almost no discomfort A: Neither B B: Discomfort felt B: Discomfort felt strongly Evaluation criteria for improvement of symptoms when going out
- AAA Itching has been greatly reduced AA: Itching has been reduced A: Itching has been slightly reduced BB: Itching has not changed B: Itching has become severe Effect of using at bedtime, symptoms of getting up the next morning Degree of improvement
- AAA Itching has been greatly reduced AA: Itching has been reduced A: Itching has been slightly reduced BB: Itching has not changed B: Itching has become severe Effect of use at bedtime, nose when waking up the next morning Jam improvement degree
- AAA The stuffy nose is greatly reduced A A: The stuffy nose is reduced A: The stuffy nose is slightly reduced B B: The stuffy nose does not change B: The stuffy nose becomes severe
- the above-mentioned commercially available nasal preparations contain a vasoconstrictor, an antihistamine, a bactericide, a fragrance and the like.
- nasal discomfort and nasal congestion were observed when awakened, and the patient sometimes awakened at night due to nasal congestion.
- the ophthalmic preparation and the nasal preparation containing the preparation according to the present invention have no irritating symptoms at the time of ophthalmic or nasal in any of the formulations, and the effect of 10 to 15 minutes is required until the effect appears. There was an interval.
- the efficacy of the ophthalmic and nasal preparations containing the preparations of the present invention is 3 hours or more, and it is possible to eliminate itching, nasal congestion and nasal allergy symptoms by using 4 to 5 times a day. did it.
- the ophthalmic preparation and the nasal preparation having the preparation according to the present invention were used at bedtime, they resulted in a good sleep and relief from nasal congestion and itchiness when getting up the next morning.
- the preparation containing both DNA and pectin alleviated nasal congestion and itch symptoms and increased the comfort level the next morning.
- the symptom-reducing effect was reinforced by appropriately adding chlorpheniramine maleate, glycyrrhizin, pyridoxine, naphazoline hydrochloride, and benzalkonidum chloride to the ophthalmic preparations and nasal preparations of the above Examples.
- the preparation for preventing contact of the present invention was applied to a mask, and the effect of capturing the pathogenic substance was verified.
- aqueous solution containing 0.5% pectin and 0.5% DNA was prepared. About 1 to 3 pieces of cotton gauze were immersed in this aqueous solution, sandwiched between several pieces of dried cotton gauze, and attached to a commercially available mask to obtain a mask for capturing disease-causing substances.
- an aqueous solution containing 0.5% pectin and 0.5% DNA was stored in a spray container to be used as a mask spray.
- An appropriate amount of the above solution was sprayed from the mask spray onto a sales mask to prepare a mask for capturing disease-causing substances.
- the anti-contact preparation according to the present invention was applied to a gargle preparation, and the oral and pharyngeal washing effects were verified.
- aqueous solution containing 0.05 ° / 0 ⁇ Kuctin and 0.05 ° / 0 DNA was prepared, and was then made into a preparation.
- an aqueous disinfectant such as Popidone JP2004 / 006992
- Sodium cromoglycate (1.0%) was added as an antiallergic agent to an aqueous solution containing 0.5% pectin and 0.5% DNA to prepare eye drops.
- the symptom-improving effect quickly appeared, and there was no problem in the feeling of use.
- the eye drops according to this example clearly showed an excellent effect in both the degree of symptom improvement and the duration of the effect.
- Example 11 Synergistic effect observed in a combination of a steroid and a preparation for preventing contact with a disease-causing substance
- Betamethasone phosphate (0.005%) was added as a steroid agent to an aqueous solution containing 0.5% pectin and 0.5% DNA to prepare eye drops.
- the symptom-improving effect quickly appeared, and a comfortable feeling of use was exhibited.
- the ophthalmic solution of this example was clearly superior in both the degree of symptom improvement and the duration of the effect.
- pectin, 0.8o / o DNA-sodium salt, and 0.8% pectin, 0.2% at the inflammatory eczema site inside the left elbow of subjects with chronic atopic dermatitis % DNA-Na salt was administered dropwise.
- the pruritus of the skin before administration completely disappeared after 2-3 hours. The effect continued from the next day. Apparent skin eczema improved to a state indistinguishable from normal sites.
- the preparation according to the present embodiment is used as a therapeutic agent for an endogenous factor such as an endocrine disrupting substance.
- an endogenous factor such as an endocrine disrupting substance.
- the preparation of the skin or mucous membrane containing at least one of a peronic acid-containing polysaccharide and a nucleic acid is used. It is a therapeutic preparation for inflammatory diseases. That is, the therapeutic formulation contains peruronic acid-containing polysaccharides or nucleic acids, or contains both peruronic acid-containing polysaccharides and nucleic acids.
- a structure having a side chain can enclose a different molecule in its three-dimensional structure. In fact, it is believed that this property is responsible for the uniform distribution of insoluble components in solution, such as yogurt and jam.
- nucleic acids In addition to nucleic acids, nucleic acids also absorb small molecules in the gaps of the double helix.
- mucosal inflammation is caused by the release of chemical mediators such as endogenous histamine and leutriene, as well as by site chemistry including IL-3, IL-5, IL-6, IL-10, IL-13, and TNF-. It is thought that not only the inflammatory cycle, such as enhanced production of proteins, has a great effect, but also unknown medium or large molecules function.
- preparations containing peronic acid-containing polysaccharides or nucleic acids contain various inflammation-related components in their three-dimensional structure, 2004/006992
- the content of the functional ingredient in the drug product is one of the polysaccharides containing peronic acid.
- the concentration in the drug product is 0.03% to 3%, most preferably 0.1% to 1%.
- % Is effective, and for DNA, one of the nucleic acids, 0.03% to 3%, most preferably 0.05% to 1% is appropriate.
- eye drops of preparations containing peronic acid-containing polysaccharides or nucleic acids incorporate inflammatory-related components into the three-dimensional structure by a completely different mechanism from conventional ophthalmic preparations, regardless of the inflammatory-related substance. It masks mucous membranes and inflammatory cells and eliminates or relieves inflammation around the conjunctiva.
- this product can capture not only water-soluble but also lipophilic inflammation-related components due to its ester structure having a side chain.
- the content of the functional ingredient in the preparation is one of the polysaccharides containing peronic acid.
- the concentration in the preparation is from 0.03% to 3%, most preferably, 0.1. / 0 to 1% is effective, and in the case of DNA which is one of nucleic acids, 0.03% to 3%, most preferably 0.05 to 1% is appropriate.
- this preparation may be applied to products worn on the living body, such as filters and masks, to protect the living body from various toxic substances such as carcinogens and endocrine disrupting substances.
- Toxic carcinogens such as molds), tar, nitrosamine, formaldehyde (also known as sick house in newly built homes), toxic carcinogens such as diesel exhaust, dioxins, tributyltin, 4-otachinolepheno Nore, noyulpheno monole, di-n-butyl phthalate, octachlorostyrene, benzophenone, dicyclohexynole phthalate, di-2-ethylaminohexyl phthalate, and four substances (butyl benzyl phthalate, getyl phthalenolate, Endocrine disrupting substances, such as di-2-ethylhexyl adipate and triphenyltin), are overflowing in the workplace and daily living space, but as a result humans are unable to perceive the above substances, resulting in unconsciousness. Has been exposed to
- the structure having an ionic and ester-type side chain is thought to be able to enclose various carcinogens and endocrine disrupting substances in the three-dimensional structure.
- nucleic acids can absorb carcinogens and endocrine disrupting substances in the gaps of the double helix structure, and can bind strong ionic molecules. Therefore, a preparation composed of these two is useful for protecting the living body from toxic substances.
- a non-woven fabric was impregnated with an aqueous solution of pectin (USPL 1%) and dried, and then a filter having a diameter of 8 cm was cut out.
- USPL 1 aqueous solution of pectin
- this filter was loaded with 100 ppm of tomelene and 100 ppm of hexane at a flow rate of 15 L / min. And ox-hexane concentrations decreased to 50 and 80 ppm, respectively. Toluene and cyclo in control There was no decrease in the concentration of xan.
- the preparations and the method for preventing contact according to the present invention are effective mainly for reducing the exposure of living bodies to exogenous disrupting factors and for reducing the severity thereof, protecting against infectious pathogens, and preventing the progression of disease states.
- it is suitable for protection against pollen allergy and prevention of progression of the disease state.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04733453A EP1625851A4 (en) | 2003-05-16 | 2004-05-17 | PREPARATION FOR PREVENTING CONTACT OF PATHOGEN BROOMS WITH A LIVING ORGANISM |
JP2005506285A JP4851185B2 (ja) | 2003-05-16 | 2004-05-17 | アレルギー症状抑制剤及び空気濾過フィルター |
US10/556,941 US20060293263A1 (en) | 2003-05-16 | 2004-05-17 | Preparation for preventing contact of pathogenic matter with living organism |
US12/422,543 US8802641B2 (en) | 2003-05-16 | 2009-04-13 | Method for inhibiting onset of or treating pollen allergy |
US14/299,503 US9433637B2 (en) | 2003-05-16 | 2014-06-09 | Method for inhibiting influenza virus infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-139380 | 2003-05-16 | ||
JP2003139380 | 2003-05-16 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/556,941 A-371-Of-International US20060293263A1 (en) | 2003-05-16 | 2004-05-17 | Preparation for preventing contact of pathogenic matter with living organism |
US10556941 A-371-Of-International | 2004-05-17 | ||
US12/422,543 Division US8802641B2 (en) | 2003-05-16 | 2009-04-13 | Method for inhibiting onset of or treating pollen allergy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004100966A1 true WO2004100966A1 (ja) | 2004-11-25 |
Family
ID=33447333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006992 WO2004100966A1 (ja) | 2003-05-16 | 2004-05-17 | 病態起因物質の生体への接触防止用製剤 |
Country Status (4)
Country | Link |
---|---|
US (3) | US20060293263A1 (ja) |
EP (1) | EP1625851A4 (ja) |
JP (1) | JP4851185B2 (ja) |
WO (1) | WO2004100966A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011148648A1 (ja) * | 2010-05-28 | 2011-12-01 | 株式会社ワイ’ズ | インフルエンザウイルスの感染抑制剤 |
US8765133B2 (en) | 2005-08-29 | 2014-07-01 | Japan Science And Technology Agency | Method of producing anti-CD166 antibody in ostrich |
JP2014172842A (ja) * | 2013-03-07 | 2014-09-22 | Pias Arise Kk | 花粉症抑制用組成物、化粧料、外用剤、医薬部外品および花粉症抑制用組成物の使用方法 |
JP2015096558A (ja) * | 2015-02-19 | 2015-05-21 | 小林製薬株式会社 | インフルエンザウイルスの感染抑制剤 |
US9095603B2 (en) | 2006-04-05 | 2015-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-allergy compositions |
JP2017019861A (ja) * | 2016-10-19 | 2017-01-26 | 小林製薬株式会社 | インフルエンザウイルスの感染抑制剤 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4851185B2 (ja) * | 2003-05-16 | 2012-01-11 | ジェレックスインターナショナル株式会社 | アレルギー症状抑制剤及び空気濾過フィルター |
FR3023166B1 (fr) * | 2014-07-07 | 2018-01-12 | Laboratoires Rivadis Sas | Utilisation d'une composition pharmaceutique renfermant une pectine a titre de principe actif, dans la prevention et/ou le traitement des lesions cutanees impliquant un caractere inflammatoire |
CA3143071A1 (en) * | 2019-07-26 | 2021-02-04 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07330617A (ja) * | 1994-06-10 | 1995-12-19 | Meiji Milk Prod Co Ltd | アレルギー性疾患予防及び治療剤 |
JP2000004881A (ja) * | 1998-06-22 | 2000-01-11 | Otsuka Pharmaceut Factory Inc | 核酸塩基結合オリゴマー |
JP2000262247A (ja) * | 1999-03-19 | 2000-09-26 | Asama Kasei Kk | 免疫調節剤、免疫調節食品および免疫調節飼料 |
JP2001233777A (ja) * | 2000-02-25 | 2001-08-28 | Yakult Honsha Co Ltd | アレルギー性疾患予防・治療剤 |
JP2001520181A (ja) * | 1997-10-17 | 2001-10-30 | ラボラトワール・ビオ・スフェール 99 | 植物抽出物に基づく組成物 |
JP2004059440A (ja) * | 2002-07-25 | 2004-02-26 | Mikasa Seiyaku Co Ltd | 肌荒れ防止および粘膜修復剤 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69031052T2 (de) * | 1989-04-21 | 1998-01-08 | Asahi Optical Co Ltd | Funktionelles Papier und seine Verwendung als Deodorant, Filtermedium oder Adsorptionsmittel |
JPH0490762A (ja) * | 1990-08-02 | 1992-03-24 | Kuraray Co Ltd | 花粉症アレルゲンの除去材 |
AU1052492A (en) * | 1991-01-31 | 1992-08-06 | Farmitalia Carlo Erba S.R.L. | Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent |
US5869457A (en) | 1991-03-11 | 1999-02-09 | Rijksuniversiteit Te Groningen | Modified proteins and their use for controlling viral infections |
NL9100434A (nl) * | 1991-03-11 | 1992-10-01 | Rijksuniversiteit | Farmaceutische preparaten voor de bestrijding van virale infecties en immuundeficientieziekten, de bereiding en toepassing daarvan. |
AU739601B2 (en) * | 1991-07-03 | 2001-10-18 | Meditech Research Limited | Use of hyaluronan in gene therapy |
JPH06116152A (ja) * | 1992-10-08 | 1994-04-26 | Nendo Kagaku Kenkyusho:Kk | 水虫治療薬 |
US5633003A (en) * | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
US5888984A (en) * | 1994-05-12 | 1999-03-30 | Dermal Research Laboratories, Inc. | Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
JPH07330716A (ja) | 1994-06-09 | 1995-12-19 | Toray Ind Inc | ナイロン6解重合法 |
JPH0899860A (ja) * | 1994-09-30 | 1996-04-16 | Kose Corp | 皮膚外用剤 |
KR20000016669A (ko) | 1996-06-14 | 2000-03-25 | 몽고메리 죤 에이 | 뉴라미니다제 저해제로 유용한 치환된 시클로펜탄 화합물 |
AU7563798A (en) | 1997-04-30 | 1998-11-24 | Emory University | Methods and compositions for administering dna to mucosal surfaces |
CA2294988C (en) * | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
US6596699B2 (en) * | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
US6235725B1 (en) * | 1998-10-30 | 2001-05-22 | Baker Norton Pharmaceuticals, Inc. | Methods and compositions for the prevention of tolerance to medications |
US6143354A (en) * | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
JP2001131074A (ja) | 1999-08-20 | 2001-05-15 | Inst Of Physical & Chemical Res | シアル酸誘導体を有効成分として含む医薬 |
JP2001064895A (ja) | 1999-08-23 | 2001-03-13 | Mitsubishi Paper Mills Ltd | クリーンぺーパーおよびその製造方法 |
JP4206456B2 (ja) * | 1999-09-09 | 2009-01-14 | 日生バイオ株式会社 | 紫外線照射による水不溶性dna架橋体の製造方法と該架橋体の環境浄化材料としての利用 |
SE9904121D0 (sv) * | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobe biomolecular structure |
NZ520312A (en) * | 1999-12-28 | 2003-08-29 | Bioniche Life Sciences Inc | Hyaluronic acid in the treatment of cancer |
US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
JP4670161B2 (ja) | 2000-07-13 | 2011-04-13 | マツダ株式会社 | 自動車の電動パワーステアリング装置 |
WO2002032406A2 (en) * | 2000-10-18 | 2002-04-25 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
US6320030B1 (en) * | 2000-10-26 | 2001-11-20 | Ashok K Shukla | Mucin-biomolecules complex for transfection |
IL140844A0 (en) * | 2001-01-10 | 2002-02-10 | Polygene Ltd | Cationic polysaccharide compositions |
JP2004107295A (ja) * | 2002-09-20 | 2004-04-08 | National Agriculture & Bio-Oriented Research Organization | ヒスタミン遊離抑制剤 |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
JP4851185B2 (ja) * | 2003-05-16 | 2012-01-11 | ジェレックスインターナショナル株式会社 | アレルギー症状抑制剤及び空気濾過フィルター |
EP1968094A3 (en) * | 2004-06-04 | 2010-01-06 | Massachusetts Institute of Technology | Non-axisymmetric charged-particle beam system |
HUE031222T2 (en) | 2007-12-20 | 2017-06-28 | Hilco Patent Acquisition 55 Llc | Devices and Procedures for Synchro-Direction Timing Synchronization |
JP5996837B2 (ja) * | 2010-05-28 | 2016-09-21 | 小林製薬株式会社 | インフルエンザウイルスの感染抑制剤 |
-
2004
- 2004-05-17 JP JP2005506285A patent/JP4851185B2/ja not_active Expired - Lifetime
- 2004-05-17 WO PCT/JP2004/006992 patent/WO2004100966A1/ja active Application Filing
- 2004-05-17 EP EP04733453A patent/EP1625851A4/en not_active Withdrawn
- 2004-05-17 US US10/556,941 patent/US20060293263A1/en not_active Abandoned
-
2009
- 2009-04-13 US US12/422,543 patent/US8802641B2/en not_active Expired - Fee Related
-
2014
- 2014-06-09 US US14/299,503 patent/US9433637B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07330617A (ja) * | 1994-06-10 | 1995-12-19 | Meiji Milk Prod Co Ltd | アレルギー性疾患予防及び治療剤 |
JP2001520181A (ja) * | 1997-10-17 | 2001-10-30 | ラボラトワール・ビオ・スフェール 99 | 植物抽出物に基づく組成物 |
JP2000004881A (ja) * | 1998-06-22 | 2000-01-11 | Otsuka Pharmaceut Factory Inc | 核酸塩基結合オリゴマー |
JP2000262247A (ja) * | 1999-03-19 | 2000-09-26 | Asama Kasei Kk | 免疫調節剤、免疫調節食品および免疫調節飼料 |
JP2001233777A (ja) * | 2000-02-25 | 2001-08-28 | Yakult Honsha Co Ltd | アレルギー性疾患予防・治療剤 |
JP2004059440A (ja) * | 2002-07-25 | 2004-02-26 | Mikasa Seiyaku Co Ltd | 肌荒れ防止および粘膜修復剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1625851A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765133B2 (en) | 2005-08-29 | 2014-07-01 | Japan Science And Technology Agency | Method of producing anti-CD166 antibody in ostrich |
US8815244B2 (en) * | 2005-08-29 | 2014-08-26 | Japan Science And Technology Agency | Method for production of antibody using ostrich |
US9095603B2 (en) | 2006-04-05 | 2015-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-allergy compositions |
WO2011148648A1 (ja) * | 2010-05-28 | 2011-12-01 | 株式会社ワイ’ズ | インフルエンザウイルスの感染抑制剤 |
JP2011246409A (ja) * | 2010-05-28 | 2011-12-08 | Y's Corp | インフルエンザウイルスの感染抑制剤 |
JP2014172842A (ja) * | 2013-03-07 | 2014-09-22 | Pias Arise Kk | 花粉症抑制用組成物、化粧料、外用剤、医薬部外品および花粉症抑制用組成物の使用方法 |
JP2015096558A (ja) * | 2015-02-19 | 2015-05-21 | 小林製薬株式会社 | インフルエンザウイルスの感染抑制剤 |
JP2017019861A (ja) * | 2016-10-19 | 2017-01-26 | 小林製薬株式会社 | インフルエンザウイルスの感染抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004100966A1 (ja) | 2006-08-03 |
US9433637B2 (en) | 2016-09-06 |
US20060293263A1 (en) | 2006-12-28 |
US20090202601A1 (en) | 2009-08-13 |
JP4851185B2 (ja) | 2012-01-11 |
EP1625851A4 (en) | 2007-12-26 |
US20140350092A1 (en) | 2014-11-27 |
EP1625851A1 (en) | 2006-02-15 |
US8802641B2 (en) | 2014-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9433637B2 (en) | Method for inhibiting influenza virus infection | |
Bartemes et al. | Innate and adaptive immune responses to fungi in the airway | |
JP6908568B2 (ja) | 病原性バイオフィルムと関連した状態を治療するための物質および方法 | |
WO2002042484A2 (de) | Verfahren zur herstellung von pektinhydrolyseprodukten | |
CN105148253A (zh) | 皮肤粘膜抗菌组合物 | |
DE60223037T2 (de) | Chitin-mikropartikel und ihre medizinische verwendung | |
WO2008072988A1 (en) | Honey based compositions of a consistency that can be delivered to the respiratory system | |
CN110840826A (zh) | 一种鼻阻隔剂及其制备方法 | |
US20220160624A1 (en) | Eye drops containing chitosan nanoparticles in which pdrn is encapsulated, and preparation method therefor | |
KR101075006B1 (ko) | 아토피 피부염 예방 및 치료용 조성물 | |
EP1411977A1 (de) | Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen | |
EP2985019B1 (en) | Nasal composition having anti-viral properties | |
KR100603069B1 (ko) | 수용성의 산성 베타 글루칸을 주성분으로하는 염증 치료용조성물 | |
KR101976560B1 (ko) | 건조 추출물들을 생산하는 방법 | |
US20060251672A1 (en) | Composition and methods of treating allergies with reishi extract | |
CH699471B1 (de) | Zubereitung zur Prävention und/oder Behandlung und/oder Verhinderung der Weiterverbreitung von Atemwegserkrankungen. | |
KR101706536B1 (ko) | 하이드로라이즈드 복합 아미노산을 포함하는 가습기용 조성물 및 이를 이용한 가습방법. | |
JPH06237979A (ja) | 室内環境改善物質 | |
EP2985027B1 (en) | Nasal composition comprising mixture of hyaluronic acids and saline solution | |
Sari et al. | Biocoagulant of blood based on chitosan nanoparticle from crustacea | |
US20110065911A1 (en) | Method for producing a bioactive glucan product substantially free of endotoxin contamination | |
CN115154512B (zh) | 一种抑菌剂及其制备方法和用途 | |
JP2004099613A (ja) | 自己免疫疾患治療用ガノデルマルシダム胞子 | |
TWI308871B (en) | Preparation of alkali soluble polysaccharides from panax quinquefolium, process for making and use in enhancing immunity of the same | |
US20240122964A1 (en) | Compositions and methods to reduce infiltration of pathogenic and anthropogenic environmental factors into the brain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006293263 Country of ref document: US Ref document number: 2005506285 Country of ref document: JP Ref document number: 10556941 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004733453 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004733453 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10556941 Country of ref document: US |